Sporadic inclusion body myositis (IBM) is the most frequent acquired myopathy seen in adults aged over 50 years. Despite the presence of conspicuous inflammatory infiltrates, sporadic IBM is essentially resistant to immunosuppressive treatment and carries an ominous prognosis. In this issue of Brain, two long-term observational studies re-examine the course and prognosis of this enigmatic disease (Benveniste et al., 2011; Cox et al., 2011) . The paper by Cox et al. (2011) reports on a Dutch cohort of 64 patients with sporadic IBM followed for a median of 12 years, and the paper by Benveniste et al. (2011) describes a French-British cohort of 136 patients followed for a median of 8.6 years ( Table 1) .
Viewed together, the new studies confirm previous observations (e.g., Lotz et al., 1989) , and substantiate a number of text book features of sporadic IBM, such as the age of onset ($60 years, with considerable variation), male preponderance (male/female ratio 67% in the Dutch and 57% in the French/British study), relentless progression (mean/median time to wheel chair 14-16 years) and characteristic distribution of affected muscles (finger flexors, quadriceps, lower leg muscles with relative sparing of shoulder and hip abductors and neck muscles). The mean rate of decline in muscle strength was surprisingly consistent across both studies despite the fact that different methods and scores were used. For example, the mean (AE SD) decline in muscle strength per year was 3.5 AE 1.6% by manual muscle testing (using the MRC score; Cox et al., 2011) , 5.4 AE 3.5% by quantitative muscle testing (Cox et al., 2011) and $4% by sporadic IBM weakness composite index (IWCI; estimated from Fig. 1 in Benveniste et al., 2011) . In individual patients, the rate of progression may be considerably slower or faster than these mean values: for example, progression tends to be more rapid in men, and in patients with late onset disease (Peng et al., 2000; Badrising et al., 2005; Benveniste et al., 2011) . Further, the progression rate varies between muscle groups: the lower leg muscles show the greatest decline, followed by forearm and upper leg muscles (Cox et al., 2011) .
Both studies show that the life expectancy is essentially normal in sporadic IBM, and at the same time, cast a gloomy light on the misery of the end-stage disease. Causes of death are related to respiratory dysfunction, aspiration, dysphagia and cachexia. During the terminal phase of illness, 3 of 46 (6.5%) patients in the Dutch study requested euthanasia because of unbearable suffering, and terminal deep sedation was applied in three additional patients because of disabling swallowing dysfunction, dehydration and cachexia (two patients), or respiratory insufficiency in the setting of pneumonia (one patient). Overall, euthanasia or terminal sedation was used in 13% of patients with sporadic IBM in the Netherlands, as compared with 17% of Dutch patients with amyotrophic lateral sclerosis (Cox et al., 2011) . This situation emphasizes the need for appropriate palliative care during progressive neuromuscular disorders such as sporadic IBM, which may be one of the most important messages of the new studies. As has been shown in oncology, early integration of palliative care services into the overall management plan may relieve suffering and even prolong life (Temel et al., 2010) .
Inevitably, the studies touch upon the controversial issue of sporadic IBM treatment. In the French/British study, 52% of the patients received at least one immunosuppressive treatment, more frequently in the French than in the British cohort. The most frequently used medication was prednisone, often in combination with other immunosuppressive agents. Overall, 56.3% of patients were treated with intravenous immunoglobulins, 32.4% with methotrexate, 36.8% with azathioprine and 2.8% with cyclophosphamide (Benveniste et al., 2011) . The treated patients tended to be younger at disease onset, and they had more frequently been initially misdiagnosed as having polymyositis. Surprisingly, at the last examination the treated cohort showed more severe weakness and more rapid progression (Benveniste et al., 2011) . This may reflect a selection bias because more severely affected patients tend to be treated more aggressively. As a counter-argument, the authors note that it was the younger cases who were treated more frequently, although they were less severely affected than older patients (Benveniste et al., 2011) . In the Dutch study, 21 of 64 patients participated in a placebo-controlled trial of methotrexate, which turned out negative. From these observations one cannot conclude that immunosuppressive treatment made IBM worse, but it is clear that such treatment had no beneficial effect.
Several sets of diagnostic criteria have been proposed for sporadic IBM (Griggs et al., 1995; Verschuuren et al., 1997; Hilton-Jones et al., 2010) . Since no one has been evaluated rigorously using prospective trial design, it is of interest how they performed in the new studies. In the Dutch study, patients were diagnosed according to the European Neuromuscular Centre criteria (Table 2; Table 2 Hilton-Jones et al. (2010) (based on Griggs et al., 1995) ; see Table 3 Distribution of patients across diagnostic categories study according to the criteria proposed by Hilton-Jones et al., 2010; Table 3 ). The median delay between first symptoms and the diagnosis of sporadic IBM was 59 months (Benveniste et al., 2011) . Notably, 30% of the patients initially received an incorrect diagnosis (polymyositis, 16.9%; muscular dystrophy, 2.9%, amyotrophic lateral sclerosis 2.2%, other diagnoses, 8.8%; Benveniste et al., 2011) . This is consistent with a recent study from the Mayo Clinic which showed that 37% (16/43) of patients with biopsy features of polymyositis (who lacked the recognized canonical biopsy features of sporadic IBM) have the clinical features of IBM, and are largely resistant to immunosuppressive therapy (Chahin and Engel, 2008) . Mainly to accommodate such patients, the category of 'Clinically defined sporadic IBM' was introduced in the modified criteria proposed by Hilton-Jones et al. 2010 (Table 3 ). Further evaluation is required before the advantages and disadvantages of the modified criteria can be fully judged. The lack of effective therapy emphasizes the need for understanding the aetiology and pathogenesis of sporadic IBM. Mainly three, not mutually exclusive, theories have been proposed that have enjoyed waxing and waning popularity over the years: the 'autoimmunity' theory, the 'persistent virus' theory and the 'disturbance of protein folding/aggregation/degradation' theory (Table 4 ; see reviews by Needham and Mastaglia, 2007; Amato and Barohn, 2009; Greenberg, 2010; Dalakas, 2011) . Although progress has been made in understanding partial aspects of the pathogenesis of sporadic IBM, a validated unifying concept is lacking. Like isolated pieces of a jigsaw puzzle, the available pieces of evidence do not form a coherent picture.
The histological features of sporadic IBM are ambiguous with regard to pathogenetic mechanism(s) (Table 4) . Consider, for example, invasion of muscle fibres by CD8 + cytotoxic T cells, one of the most conspicuous features of sporadic IBM. This was present in all investigated patients in the Dutch study (Cox et al., 2011) , and in 62.5% of the patients in the French/British study (Benveniste et al., 2011 ; Table 1 ). From previous investigations, it is known that such 'auto-invasive' CD8 + T cells are clonally expanded, show signs of activation and persist on repeated muscle biopsy (reviewed in Dalakas, 2011) . All these features provide tell-tale evidence for a chronic T-cell-mediated cytotoxic injury. This would be consistent with either an autoimmune, viral or degenerative aetiology. In fact, when this phenomenon was first described in classical studies Engel, 1984, 1986; Engel and Arahata, 1984) , it was already noted that the invasion of non-necrotic muscle fibres by CD8 + T cells may occur as a rare event in Duchenne muscular dystrophy. If the CD8 + -mediated attack in sporadic IBM is autoimmune in nature, as thought to be the case in polymyositis, the disease should respond to immunosuppressive therapy. However, if the T-cell response is directed against a persistent virus or occurs secondary to degeneration, it might be totally resistant to immunosuppressive therapy. Regardless of whether inflammation is primary or secondary, the degenerative and inflammatory mechanisms of sporadic IBM seem to be closely intertwined. For example, there is evidence that the inflammatory cytokines interleukin1-b and interferon-, which are amply produced by infiltrating immune cells, can induce accumulation of b-amyloid in muscle cells (Schmidt et al., 2008) . In polymyositis, however, there is also fiber invasion but no amyloid seems to accumulate in the fibers. Table 3 Diagnostic criteria used in the French-British study (Benveniste et al., 2011) ; modified from Hilton-Jones et al. (2010) Griggs et al., 1995) Pathological criteria Invasion of non-necrotic fibers by mononuclear cells or rimmed vacuoles or increased MHC-1, but no intracellular amyloid deposits or 15-18 nm filaments In contrast to most other tissues, human leucocyte antigen (HLA)-class 1 is normally undetectable on mature muscle fibres. In sporadic IBM, however, there is widespread HLA-class 1 expression on the majority of muscle fibres, including those remote from inflammatory infiltrates. Because CD8 + T cells recognize antigenic peptides bound to HLA class 1 molecules on the target cell surface, HLA class 1 expression is a necessary but not sufficient precondition for a CD8 + T-cell-mediated attack. In fact, there is a marked discrepancy between the widespread over-expression of HLA class 1 and the strictly focal nature of the inflammatory infiltrates in sporadic IBM muscle. In a transgenic mouse model, constitutive over-expression of class 1 major histocompatibility complex molecules in muscle resulted in a necrotic myopathy and endoplasmic reticulum stress response (Nagaraju et al., 2000 (Nagaraju et al., , 2005 , indicating that upregulation of HLA class 1 in itself might be an 'upstream' pathogenetic factor in myositis (Henriques-Pons and Nagaraju, 2009) . Using laser microdissection of individual muscle fibres followed by RNA microarray profiling and quantitative PCR, we compared the transcript and protein expression profiles of attacked and non-attacked muscle fibres in sporadic IBM (Ivanidze et al., 2011) . This approach allowed us to separate transcripts from different types of muscle fibres, excluding those from inflammatory cells. With this method, we found differential upregulation of the interferon-signalling cascade in attacked but not non-attacked muscle fibres in sporadic IBM (Ivanidze et al., 2011) . Also the cell surface receptor for interferon-was preferentially localized on muscle fibres attacked by cytotoxic T cells. Thus, interferon-focally secreted by inflammatory cells can bind to the interferonreceptor on the surface of the attacked muscle fibres, inducing downstream signalling and expression of interferon--regulated proteins. The latter include subunits of the immunoproteasome, an inducible form of the proteasome enhancing and modifying HLA class 1-associated antigen presentation. In contrast to the attacked muscle fibres, however, the non-attacked fibres do not express the interferon-surface receptor or an intracellular interferon-signalling 'signature' (Ivanidze et al., 2011) . However, both attacked and non-attacked fibres are HLA class 1 + . Since the non-attacked fibres lack the interferon-surface receptor, and do not show evidence of intracellular interferon-signalling, it seems unlikely that HLA-class 1 + is induced by interferon-on these fibres.
Together, these observations suggest that the differential upregulation of interferon-receptor and interferon-signalling in attacked muscle fibres is related to focal inflammation, whereas the ubiquitous HLA class 1 expression on essentially all muscle fibres does not require expression of the interferon-receptor. This supports the view that the widespread interferon -receptor-independent upregulation of HLA-class 1 on sporadic IBM muscle fibres might represent an 'upstream' mechanism induced by unknown trigger(s). In this regard, upregulation of HLA-class 1 may be compared with upregulation of alphaBcrystallin, a heat shock or stress protein thought to be induced in sporadic IBM muscle fibres by an as yet unidentified upstream Table 4 Arguments pro and contra the major theories of sporadic IBM pathogenesis/aetiology as discussed in the literature (Needham and Mastaglia, 2007; Amato and Barohn, 2009; Greenberg, 2010; Dalakas, 2011) Please note that the list is meant to be a thought-provoking impulse rather than exhaustive compilation of scientific evidence. MHC = major histocompatibility complex.
